Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor

Why did U.S. Steel shares surge today? How will Trump’s US-UK trade deal impact tariffs? Why is Meta introducing ads on WhatsApp now? What caused AMD stock to jump 9% recently? How is Israel-Iran conflict affecting global markets? Why did At Home file for bankruptcy? What are implications of Senate’s SALT deduction cap?

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor

benzinga.com/news/health-care/25/06/45954557/ozempic-patent-expires-in-canada-after-novo-nordisk-fails-to-pay-450-fee-its-the-second-largest-

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue.
What Happened: About a week ago, Sandoz Group AG (OTC:SDZNY) CEO Richard Saynor, in an interview with EndPoint…

This story appeared on benzinga.com, 2025-06-16 16:01:05.